JP2022538117A5 - - Google Patents
Info
- Publication number
- JP2022538117A5 JP2022538117A5 JP2021576582A JP2021576582A JP2022538117A5 JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5 JP 2021576582 A JP2021576582 A JP 2021576582A JP 2021576582 A JP2021576582 A JP 2021576582A JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107324A JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867032P | 2019-06-26 | 2019-06-26 | |
| US62/867,032 | 2019-06-26 | ||
| PCT/US2020/039687 WO2020264211A1 (en) | 2019-06-26 | 2020-06-25 | Anti-cd33 antibodies for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107324A Division JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538117A JP2022538117A (ja) | 2022-08-31 |
| JP2022538117A5 true JP2022538117A5 (https=) | 2023-07-03 |
| JP7788859B2 JP7788859B2 (ja) | 2025-12-19 |
Family
ID=74059823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576582A Active JP7788859B2 (ja) | 2019-06-26 | 2020-06-25 | がんを処置するための抗ｃｄ３３抗体 |
| JP2025107324A Pending JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107324A Pending JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220251192A1 (https=) |
| EP (1) | EP3990022A4 (https=) |
| JP (2) | JP7788859B2 (https=) |
| CN (1) | CN114401744B (https=) |
| CA (1) | CA3149683A1 (https=) |
| WO (1) | WO2020264211A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020264211A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CA3180445A1 (en) * | 2020-05-27 | 2021-12-02 | Brian H. SANTICH | Anti-gd2 sada conjugates and uses thereof |
| EP4608871A1 (en) * | 2022-10-26 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | Cd33 antibody compositions for treating alzheimer's disease |
| CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
| CN118580357A (zh) * | 2024-08-07 | 2024-09-03 | 上海交通大学医学院附属仁济医院 | 一种cd33特异性单克隆抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| ZA200503075B (en) * | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP3145542A4 (en) * | 2014-05-20 | 2018-01-17 | ImmunoGen, Inc. | Methods for characterizing and treating acute myeloid leukemia |
| TWI719942B (zh) * | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| WO2018014001A1 (en) * | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| RU2019114863A (ru) * | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| EA201992546A1 (ru) * | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
| AU2018261891B2 (en) * | 2017-05-05 | 2024-11-21 | Memorial Sloan Kettering Cancer Center | Modular self assembly disassembly (SADA) technologies |
| EP3624839A4 (en) * | 2017-05-17 | 2021-06-16 | Immunogen, Inc. | DOSING PLANS FOR ANTI-CD33 IMMUNE CONJUGATES |
| ES3057687T3 (en) * | 2017-07-06 | 2026-03-04 | Memorial Sloan Kettering Cancer Center | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy |
| KR20200070254A (ko) * | 2017-09-22 | 2020-06-17 | 이뮤노젠 아이엔씨 | 면역접합체에서 메티오닌 산화를 방지하는 방법 |
| US20190153096A1 (en) * | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| WO2020264211A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
-
2020
- 2020-06-25 WO PCT/US2020/039687 patent/WO2020264211A1/en not_active Ceased
- 2020-06-25 CA CA3149683A patent/CA3149683A1/en active Pending
- 2020-06-25 JP JP2021576582A patent/JP7788859B2/ja active Active
- 2020-06-25 EP EP20831640.6A patent/EP3990022A4/en active Pending
- 2020-06-25 US US17/621,815 patent/US20220251192A1/en active Pending
- 2020-06-25 CN CN202080059807.6A patent/CN114401744B/zh active Active
-
2025
- 2025-06-25 JP JP2025107324A patent/JP2025175994A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538117A5 (https=) | ||
| JP2022546572A5 (https=) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| JP2022525435A5 (https=) | ||
| US11427648B2 (en) | Anti-CD146 antibodies and uses thereof | |
| JP5085005B2 (ja) | 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法 | |
| JP2023523584A5 (https=) | ||
| JP5110768B2 (ja) | モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用 | |
| Welt et al. | Phase I study of anticolon cancer humanized antibody A33 | |
| JP5155356B2 (ja) | モノクローナル抗体ｈＰＡＭ４ | |
| KR101002443B1 (ko) | Ｒｓ7 항체 | |
| JP2020523029A5 (https=) | ||
| JP2021517816A5 (https=) | ||
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| JP2023537002A5 (https=) | ||
| JP2022540611A5 (https=) | ||
| JP2020534017A5 (https=) | ||
| CA3062335A1 (en) | Use of anti-b7h3 antibodies for treating cancer in the central nervous system | |
| Oriuchi et al. | Current status of cancer therapy with radiolabeled monoclonal antibody | |
| JP2024530166A5 (https=) | ||
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| CN115379848A (zh) | 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 | |
| Lindland et al. | Preclinical evaluation of PTK7-targeted radionuclide therapy | |
| JP2024531913A5 (https=) | ||
| KR20250017214A (ko) | 항cd44v6 항체 및 이들의 cd44v6 과발현 암 치료의 용도 |